<DOC>
	<DOCNO>NCT00965523</DOCNO>
	<brief_summary>The purpose study ( E7389-J081-224 ; hereafter refer Study 224 ) evaluate safety patient continue receive E7389 complete Phase II clinical study ( E7389-J081-221 ; hereafter refer Study 221 ) E7389 advance relapse breast cancer intravenously administer E7389 .</brief_summary>
	<brief_title>Study E7389 Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>Study 224 ( Extension Period ) design evaluate safety efficacy E7389 collect data subject continue receive E7389 transfer Study 221 ( Core Period ) . Thus , efficacy analysis perform Study 221 update report additional data collect Study 224 . Objective response rate ( ORR ) number subject adverse event report outcome measure outcome measure Study 221 main study combine data . Also , safety analysis perform Study 221 update report additional data collect Study 224 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Female patient histologically cytologically confirm breast cancer . 2 . Patients receive prior chemotherapy include anthracycline taxane . 3 . Patients age 20 74 year give informed consent give write voluntary consent participate study completion Study 221 . 4 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 . 5 . Patients measurable lesion . 6 . Patients expect survival ≥ 3 month start study drug therapy . 7 . Female patient continue administration E7389 follow Study 221 useful . 8 . Patients meet criterion start next cycle Study 221 . Namely , patient meet following criterion : 1 . Neutrophil count &gt; = 1,500 /µL 2 . Platelet count &gt; = 100,000 /µL 3 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 2.5 time upper limit normal ( ULN ) facility &lt; = 5 time ULN patient hepatic metastasis ) 4 . Total bilirubin &lt; = 1.5 time ULN 5 . Serum creatinine &lt; = 1.5 time ULN 6 . Nonhematological toxicity &lt; = Grade 2 ( exclude diseaseassociated event laboratory abnormality without clinical symptom ) Exclusion criterion : 1 . Patients systemic infection fever ( ≥38.0°C ) . 2 . Patients pleural effusion , ascites pericardial fluid require drainage . 3 . Patients brain metastasis present clinical symptom . 4 . Pregnant woman , nurse mother , premenopausal woman childbearing potential . Premenopausal woman childbearing potential defined woman &lt; 12 month late menstruation positive pregnancy test perform enrollment take test consent take appropriate contraceptive measure . Postmenopausal woman must amenorrheic least 12 month make sure potential become pregnant . 5 . Patients serious complication : 1 . Patients uncontrollable cardiac disease ischemic heart disease arrhythmia level severity need treat ( exclude leave ventricular hypertrophy , mild leave ventricular volume overload mild right leg block accompany hypertension ) 2 . Patients myocardial infarction within 6 month prior study entry 3 . Patients complication hepatic cirrhosis 4 . Patients interstitial pneumonia pulmonary fibrosis 5 . Patients bleed tendency 6 . Patients active double cancer . 7 . Pregnant woman nurse mother . 8 . Patients receive extensive radiotherapy ( ≥30 % bone marrow ) . 9 . Patients refuse receive supportive therapy blood transfusion myelosuppression . 10 . Patients participate clinical study . 11 . Patients judge principal investigator investigator inappropriate patient clinical study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>E7389</keyword>
	<keyword>Eribulin</keyword>
</DOC>